Posted inBiotechnology
Novo Nordisk stock crashes after CagriSema misses phase 3 weight-loss goal
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss…
Posted inBiotechnology
Idorsia’s sale of Tryvio falls behind schedule, but layoffs remain on track
Idorsia’s plans to sell its hypertension drug Tryvio have faced a speedbump, even as the biotech ploughs ahead with around…
Posted inBiotechnology
Aadi pulls commercial-to-preclinical pivot, buying ADCs and selling approved drug to reboot business
Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and…
Posted inBiotechnology
FDA rejects Zealand Pharma’s GLP-2 analog in rare bowel disease
The FDA has denied Zealand Pharma’s approval bid for glepaglutide—a possible challenger to Takeda’s Gattex—in short bowel syndrome (SBS), citing…
Posted inBiotechnology
Pyxis Oncology shelves antibody to focus on sole clinical asset, an ADC licensed from Pfizer
Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after sharing preliminary results…
Posted inBiotechnology
Oncology biotech Epitopea licenses Genevant nucleic acid delivery tech for up to $123M
To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery specialist Genevant Sciences…
Posted inBiotechnology
Chutes & Ladders—FDA’s principal deputy to depart agency
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please…
Posted inBiotechnology
Omeros antibody improves overall survival by 68% in rare condition, new analysis finds
Omeros is putting up its monoclonal antibody up for FDA approval—again. This time, the resubmission will be based on a…
Posted inBiotechnology
Merck’s HIV combo treatment meets the bar for viral suppression in pair of phase 3 studies
After hitting the mark in a phase 2 of its investigational islatravir paired with Gilead’s lenacapivir, Merck & Co.'s islatravir…
Posted inBiotechnology
VC firm pens $608M biobucks deal to redirect NGM’s MASH drug to rare disease
KdT Ventures has signed off on a $608 million biobucks deal for NGM Biopharmaceuticals’ phase 2-ready metabolic-dysfunction associated steatohepatitis (MASH)…